Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Founded in 2015 and based in Hong Kong, ORI Capital is a venture capital firm that focuses on early-stage investments in the biotech sector. The firm targets global opportunities and employs a proprietary quantimental strategy that combines AI-assisted big data with fundamental research. Their team includes specialists with diverse expertise, particularly in data science and scientific research.
ORI Capital invests in early-stage biotech companies, specifically in the sectors of diagnostics, drug delivery, and therapeutics. Their investment strategy emphasizes high-mortality disease areas, including cancer, cardiovascular diseases, and neurodegenerative disorders. Typical investments occur at the Seed and Series A stages.
One notable portfolio company is Semma Therapeutics, which is developing therapies for insulin-dependent diabetes using Induced Pluripotent Stem Cell (iPS) derived pancreatic islets.
Email your pitch deck to info@ori-capital.com for consideration.
ORI Capital often leads investment rounds, particularly in Seed and Series A stages, to ensure they can guide the strategic direction of their portfolio companies.
The firm is open to follow-on investments, especially for companies that demonstrate significant progress and alignment with their investment thesis.
Specific fund size details are not publicly disclosed, but ORI Capital focuses on making substantial investments in early-stage biotech companies.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.